Condition: COPD (Chronic Obstructive Pulmonary Disease) · Sponsor: Windward Bio
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms. The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
This description comes directly from the study's public registry record.
Juliana Hutchinson, MSc · +4161 551 75 75 · clinical.trial.enquiry@windwardbio.com
Always discuss trial participation with your own doctor first.
| WB Contracted Clinical Research Site | Miami Lakes, Florida, United States | Recruiting |
| WB Contracted Clinical Research Site | North Dartmouth, Massachusetts, United States | Recruiting |
| WB Contracted Clinical Research Site | Charlotte, North Carolina, United States | Recruiting |
| WB Contracted Clinical Research Site | McKinney, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07646587